{
  "kind": "treatment",
  "slug": "aniracetam",
  "type": "nootropic",
  "name": "Aniracetam",
  "summary": "A synthetic nootropic compound in the racetam family, used for potential cognitive enhancement and studied for mood and neuroprotective effects.",
  "description": "Aniracetam is a fat-soluble nootropic drug structurally related to piracetam. It is believed to modulate AMPA-type glutamate receptors and enhance cholinergic neurotransmission. It has been studied for cognitive enhancement, anxiety reduction, and neuroprotection, but evidence in humans is limited and it is not approved for medical use in the United States. It is available in some countries as a prescription drug for cognitive impairment and dementia.",
  "category": "medications/nootropics",
  "tags": [
    "nootropic",
    "racetam",
    "cognitive-enhancer",
    "experimental"
  ],
  "metadata": {
    "drug_classes": [
      "Nootropic",
      "Racetam Derivative"
    ],
    "therapeutic_categories": [
      "Cognitive Enhancement",
      "Anxiety Disorders (experimental)",
      "Neuroprotection"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Varies by country",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Reference brands vary by region"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": null,
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term (experimental)"
    ],
    "specialty_areas": [
      "Neurology",
      "Psychiatry"
    ],
    "fda_approval_year": 1978
  },
  "clinical_metadata": {
    "primary_indications": [
      "Dementia"
    ],
    "off_label_uses": [
      "Cognitive enhancement",
      "Anxiety",
      "Depression augmentation"
    ],
    "contraindications": [
      "Hypersensitivity to racetam compounds"
    ],
    "monitoring_required": [
      "Cognitive function (if prescribed)",
      "Mood changes"
    ],
    "efficacy_rating": {
      "cognition": 2,
      "anxiety": 2,
      "overall-tolerability": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "aniracetam",
      "nootropic",
      "racetam"
    ],
    "synonyms": [],
    "common_misspellings": [
      "aniracitam",
      "aniracetum"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Cognitive impairment (approved in some countries)",
        "Experimental use for anxiety and depression"
      ]
    },
    {
      "type": "mechanism",
      "text": "Positively modulates AMPA-type glutamate receptors, enhancing excitatory neurotransmission, and facilitates cholinergic signaling, which may improve learning and memory."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "750 mg twice daily (common in research and clinical use)",
        "titrate": "Adjust within range as tolerated",
        "usual_range": "750â€“1500 mg/day",
        "max": "3000 mg/day (based on clinical use in some countries)"
      },
      "geriatric": "Similar dosing; monitor closely for CNS effects",
      "hepatic_impairment": "No formal data; use caution",
      "renal_impairment": "No formal data; use caution"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets and capsules (250 mg, 400 mg, 750 mg)"
      ]
    },
    {
      "type": "onset_duration",
      "text": "May produce acute effects on cognition and mood within hours; potential benefits for dementia may require weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "headache",
        "insomnia",
        "nervousness"
      ],
      "less_common": [
        "dizziness",
        "rash"
      ],
      "serious": [
        "rare hypersensitivity reactions"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Not FDA-approved",
        "Evidence for healthy cognitive enhancement is limited"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CNS stimulants",
          "risk": "Additive stimulation",
          "action": "Monitor"
        },
        {
          "with": "Cholinergic drugs",
          "risk": "Additive effects",
          "action": "Monitor for cholinergic side effects"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Cognitive performance (if used therapeutically)",
        "Mood and anxiety symptoms"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Safety not established; avoid unless essential.",
      "lactation": "Unknown excretion; avoid unless essential.",
      "pediatrics": "Not established; avoid outside research.",
      "geriatrics": "Generally well tolerated but may cause insomnia or anxiety."
    },
    {
      "type": "tapering",
      "text": "Not required; no known withdrawal syndrome."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Fat-soluble racetam; best taken with food or fat-containing meals.",
        "Often discussed in biohacker and nootropic communities, but human evidence remains limited.",
        "Some users combine with choline supplements to reduce headaches."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "DrugBank: Aniracetam",
          "url": "https://go.drugbank.com/"
        },
        {
          "label": "Nootropics overview - Examine.com",
          "url": "https://examine.com/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Aniracetam: Nootropic Cognitive Enhancer Profile",
    "description": "Overview of aniracetam, its mechanisms, potential cognitive and mood benefits, dosing, and safety profile."
  }
}
